• DOI:10.1182/blood-2011-06-318220
• Corpus ID: 2543277

How I treat patients who mobilize hematopoietic stem cells poorly.

@article{To2011HowIT,
  title={How I treat patients who mobilize hematopoietic stem cells poorly.},
  author={Luen Bik To and Jean-Pierre L{\'e}vesque and Kirsten E. Herbert},
  journal={Blood},
  year={2011},
  volume={118 17},
  pages={
          4530-40
        }
}

• L. To, J. Lévesque, K. Herbert
• Published 27 October 2011
• Biology
• Blood

Transplantation with 2-5 × 10(6) mobilized CD34(+)cells/kg body weight lowers transplantation costs and mortality. Mobilization is most commonly performed with recombinant human G-CSF with or without chemotherapy, but a proportion of patients/donors fail to mobilize sufficient cells. BM disease, prior treatment, and age are factors influencing mobilization, but genetics also contributes. Mobilization may fail because of the changes affecting the HSC/progenitor cell/BM niche integrity and chemotaxis. Poor mobilization affects patient outcome and increases resource use. Until recently increasing G-CSF dose and adding SCF have been used in poor mobilizers with limited success. However, plerixafor through its rapid direct blockage of the CXCR4/CXCL12 chemotaxis pathway and synergy with G-CSF and chemotherapy has become a new and important agent for mobilization. Its efficacy in upfront and failed mobilizers is well established. To maximize HSC harvest in poor mobilizers the clinician needs to optimize current mobilization protocols and to integrate novel agents such as plerixafor. These include when to mobilize in relation to chemotherapy, how to schedule and perform apheresis, how to identify poor mobilizers, and what are the criteria for preemptive and immediate salvage use of plerixafor.